Ketamine Mechanisms in Treatment-Resistant Depression

Ketamine has emerged as a paradigm-shifting intervention for individuals with depression unresponsive to standard treatments. At subanesthetic doses, its primary action is the non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors on inhibitory interneurons, leading to a transient glutamatergic surge and downstream activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This sequence promotes synaptic potentiation, rapid release of brain-derived neurotrophic factor and enhancement of neuroplasticity within key mood-regulating circuits. Concurrent inhibition of HCN1 channels further modulates neuronal excitability and contributes to the characteristic oscillatory signatures observed in the prefrontal cortex and hippocampus. Functional imaging and electrophysiology have demonstrated that ketamine rapidly alters large-scale network connectivity—normalising thalamocortical and fronto-striatal interactions—while reducing pathological attentional biases and restoring emotional processing. These multiscale effects, from molecular signalling to system-wide network reorganisation, underpin ketamine’s rapid antidepressant and antisuicidal benefits and guide the development of novel, fast-acting therapeutics.

Research from Nature Portfolio

Recent studies employing intracranial recordings have delineated ketamine’s frequency-specific engagement of distinct circuits. Gamma-band oscillations in prefrontal and hippocampal regions appear to reflect the drug’s antidepressant actions, whereas 3 Hz rhythms in posteromedial cortex align with dissociative phenomena. By comparing oscillatory changes before and after GABAergic modulation, researchers have parsed the contributions of NMDA disinhibition versus HCN1 inhibition, offering dynamic biomarkers for treatment response. Complementary foundational work mapping synaptic density in major depression has shown an inverse relationship between synaptic terminal loss and symptom severity, emphasising synaptogenesis as a central target for interventions like ketamine.

Ketamine Mechanisms in Treatment-Resistant Depression publication trend

The graph below shows the total number of articles in ketamine mechanisms in treatment-resistant depression across all publications each year (not limited to Nature Index journals).

Technical terms

NMDA receptor: Ionotropic glutamate receptor whose antagonism by ketamine initiates a cascade leading to antidepressant effects.

HCN1 channel: Hyperpolarisation-activated cyclic nucleotide-gated channel that modulates neuronal excitability and contributes to ketamine’s oscillatory signatures.

Gamma oscillations: Brain rhythms (30–100 Hz) linked to synaptic activity and cognitive processing, enhanced by ketamine in mood-relevant circuits.

Synaptic density: Measure of nerve terminal number per unit volume, indicative of neuronal connectivity and plasticity.

Thalamocortical connectivity: Functional linkage between the thalamus and cortex, critical for mood regulation and information flow.

Attentional bias: Tendency to preferentially attend to certain emotional stimuli, often skewed toward negative content in depression.

Lempel–Ziv complexity (LZC): Non-linear EEG metric reflecting the unpredictability of neural signal patterns over time.

Multiscale entropy (MSE): Quantitative measure of signal complexity across multiple temporal scales, capturing dynamic brain activity.

References

1. Characterizing brain dynamics during ketamine-induced dissociation and subsequent interactions with propofol using human intracranial neurophysiology. Nature Communications (2023).
2. Lower synaptic density is associated with depression severity and network alterations. Nature Communications (2019).
3. Thalamocortical functional connectivity and rapid antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression. Molecular Psychiatry (2024).
4. The Impact of Intravenous Ketamine on Attentional Bias: Probing Mechanisms of Rapid-Acting Antidepressant Effects in Two Clinical Studies. Biological Psychiatry (2024).
5. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology (2023).